Spironolactone induces apoptosis and inhibits NF-κB independent of the mineralocorticoid receptor

Apoptosis

Volumn 11, Issue 12, 2006, Pages 2159-2165

  Sønder, Søren Ulrik Salling ^a   Woetmann, Anders ^b   Ødum, Niels ^b   Bendtzen, Klaus ^a  

^a Rigshospitalet   (Denmark)

^b UNIVERSITY OF COPENHAGEN   (Denmark)

Author keywords

Cytokines; Human mononuclear cells; Mineralocorticoid receptors; NF B; Spironolactone; Sulfasalazine

Indexed keywords

7ALPHA THIOMETHYLSPIRONOLACTONE; ALDOSTERONE ANTAGONIST; CYTOKINE; DRUG METABOLITE; EPLERENONE; I KAPPA B ALPHA; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MINERALOCORTICOID RECEPTOR; SALAZOSULFAPYRIDINE; SPIRONOLACTONE; TRANSCRIPTION FACTOR;

APOPTOSIS; ARTICLE; CELL CULTURE; CELL DEATH; CELL LINE; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOPLASM; HUMAN; HUMAN CELL; MONONUCLEAR CELL; PHOSPHORYLATION; PRIORITY JOURNAL; RECEPTOR BINDING;

ALDOSTERONE ANTAGONISTS; APOPTOSIS; CASPASE 3; CYTOKINES; HUMANS; I-KAPPA B PROTEINS; LEUKOCYTES, MONONUCLEAR; NF-KAPPA B; PHOSPHORYLATION; RECEPTORS, MINERALOCORTICOID; SPIRONOLACTONE; SULFASALAZINE;

EID: 33845371216     PISSN: 13608185     EISSN: 1573675X     Source Type: Journal    
DOI: 10.1007/s10495-006-0286-3     Document Type: Article

References (25)

1. Sonenshein GE (1997) Rel/NF-kappa B transcription factors and the control of apoptosis. Semin Cancer Biol 8:113-119
2. Pahl HL (1999) Activators and target genes of Rel/NF-kappaB transcription factors. Oncogene 18:6853-6866
3. Ali S, Mann DA (2004) Signal transduction via the NF-kappaB pathway: A targeted treatment modality for infection, inflammation and repair. Cell Biochem Funct 22:67-79
4. Chen LF, Greene WC (2004) Shaping the nuclear action of NF-kappaB. Nat Rev Mol Cell Biol 5:392-401
5. Delhalle S, Blasius R, Dicato M, Diederich M (2004) A beginner's guide to NF-kappaB signaling pathways. Ann N Y Acad Sci 1030:1-13
6. Los LE, Colby HD (1994) Binding of spironolactone metabolites in vivo to renal mineralocorticoid receptors in guinea pigs. Pharmacology 48:86-92
7. Klauber N, Browne F, Anand-Apte B, D'Amato RJ (1996) New activity of spironolactone. Inhibition of angiogenesis in vitro and in vivo. Circulation 94:2566-2571
8. Fiebeler A, Schmidt F, Muller DN, et al (2001) Mineralocorticoid receptor affects AP-1 and nuclear factor-kB activation in angiotensin II-induced cardiac injury. Hypertension 37:787-793
9. Sun Y, Zhang J, Lu L, Chen SS, Quinn MT, Weber KT (2002) Aldosterone-induced inflammation in the rat heart : Role of oxidative stress. Am J Pathol 161:1773-1781
10. Matsumoto R, Yoshiyama M, Omura T, et al (2004) Effects of aldosterone receptor antagonist and angiotensin II type I receptor blocker on cardiac transcriptional factors and mRNA expression in rats with myocardial infarction. Circ J 68:376-382
11. Sanz-Rosa D, Cediel E, de las Heras N, et al (2005) Participation of aldosterone in the vascular inflammatory response of spontaneously hypertensive rats: role of the NFkappaB/IkappaB system. J Hypertens 23:1167-1172
12. Bendtzen K, Hansen PR, Rieneck K, The Spironolactone/Arthritis Study Group (2003) Spironolactone inhibits production of proinflammatory cytokines, including tumor necrosis factor alpha and interferon-gamma, and has potential in the treatment of arthritis. Clin Exp Immunol 134:151-158
13. Hansen PR, Rieneck K, Bendtzen K (2004) Spironolactone inhibits production of proinflammatory cytokines by human mononuclear cells. Immunol Lett 91:87-91
14. Grauballe MC, Bentzen BH, Bjornsson M, et al (2005) The effect of spironolactone on experimental periodontitis in rats. J Periodontal Res 40:212-217
15. Sønder SU, Mikkelsen M, Rieneck K, Hedegaard CJ, Bendtzen K (2006) Effects of spironolactone on human blood mononuclear cells: Mineralocorticoid receptor independent effects on gene expression and late apoptosis induction. Br J Pharmacol 148:46-53
16. Mikkelsen M, Sonder SU, Nersting J, Bendtzen K (2006) Spironolactone induces apoptosis in human mononuclear cells. Association between apoptosis and cytokine suppression. Apoptosis 11:573-579
17. Wahl C, Liptay S, Adler G, Schmid RM (1998) Sulfasalazine: A potent and specific inhibitor of nuclear factor kappa B. J Clin Invest 101:1163-1174
18. Jue DM, Jeon KI, Jeong JY (1999) Nuclear factor kappaB (NF-kappaB) pathway as a therapeutic target in rheumatoid arthritis. J Korean Med Sci 14:231-238
19. Liptay S, Fulda S, Schanbacher M, et al (2002) Molecular mechanisms of sulfasalazine-induced T-cell apoptosis. Br J Pharmacol 137:608-620
20. Garthwaite SM, McMahon EG (2004) The evolution of aldosterone antagonists. Mol Cell Endocrinol 217:27-31
21. Williams TA, Verhovez A, Milan A, Veglio F, Mulatero P (2006) Protective effect of spironolactone on endothelial cell apoptosis. Endocrinology 147:2496-2505
22. Akahoshi T, Namai R, Sekiyama N, Tanaka S, Hosaka S, Kondo H (1997) Rapid induction of neutrophil apoptosis by sulfasalazine: implications of reactive oxygen species in the apoptotic process. J Leukoc Biol 62:817-826
23. Habens F, Srinivasan N, Oakley F, Mann DA, Ganesan A, Packham G (2005) Novel sulfasalazine analogues with enhanced NF-kB inhibitory and apoptosis promoting activity. Apoptosis 10:481-491
24. Lappas M, Yee K, Permezel M, Rice GE (2005) Sulfasalazine and BAY 11-7082 interfere with the nuclear factor-kappa B and I kappa B kinase pathway to regulate the release of proinflammatory cytokines from human adipose tissue and skeletal muscle in vitro. Endocrinology 146:1491-1497
25. Takamura N, Maruyama T, Ahmed S, Suenaga A, Otagiri M (1997) Interactions of aldosterone antagonist diuretics with human serum proteins. Pharm Res 14:522-526